| Identification | Back Directory | [Name]
AIM-100 | [CAS]
873305-35-2 | [Synonyms]
AIM-100
AIM 100;AIM100
5,6-Diphenyl-N-[[(2S)-tetrahydro-2-furanyl]methyl]furo[2,3-d]pyrimidin-4-amine
Furo[2,3-d]pyrimidin-4-amine, 5,6-diphenyl-N-[[(2S)-tetrahydro-2-furanyl]methyl]- | [Molecular Formula]
C23H21N3O2 | [MDL Number]
MFCD22417088 | [MOL File]
873305-35-2.mol | [Molecular Weight]
371.43 |
| Chemical Properties | Back Directory | [Boiling point ]
552.9±50.0 °C(Predicted) | [density ]
1.243±0.06 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | [solubility ]
insoluble in H2O; ≥35.8 mg/mL in EtOH with gentle warming; ≥36 mg/mL in DMSO with gentle warming | [form ]
Powder | [pka]
4.62±0.40(Predicted) |
| Hazard Information | Back Directory | [Uses]
AIM-100 modulates ligand-independent AR activity and inhibits prostate cell growth. | [Biological Activity]
aim-100 is a small inhibitor of ack1 tyrosine kinase with ic50 value of 24 nm [1].aim-100 mimicked atp and inhibited the activity of ack1 significantly and specifically. it showed no inhibition activity for the other 30 kinases including pi3-kinase and akt, and showed a five-fold higher ic50 value for lck. in mef cells treated with egf, aim-100 caused a remarkable decrease of the activation of ack1. in the human prostate cancer cells lncap and lapc4, aim-100 treatment resulted in an increase of g0/g1 cell phase and subsequent cell growth suppression. these effects of aim-100 also exerted in the pancreatic cancer cells. aim-100 induced apoptosis in panc-1 cells at concentration of 10 μm. moreover, aim-100 inhibited cell growth with gi50 values of 7 to 8 μm in cd-18, panc-1, ov90, mcf-7 and mda-mb-468 cancer cells [1, 2]. | [storage]
Store at +4°C | [References]
1. mahajan k, challa s, coppola d, et al. effect of ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. the prostate, 2010, 70(12): 1274-1285. 2. mahajan k, coppola d, chen y, et al. ack1 tyrosine kinase activation correlates with pancreatic cancer progression. the american journal of pathology, 2012, 180(4): 1386-1393. |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|